Fundz

Kynexis extends its Series A funding by €40 million, bringing the total to €97 million. The funding, led by Novartis Venture Fund, will support Phase 2 studies for its cognitive medicine.

PRIVATEAug 19, 2026

Amount Raised

€40 Million

Round Type

Series A

North HollandBiotechnologyHealth CareTherapeutics

Investors

Sunstone Life Science VenturesForbionYsios CapitalNovartis Venture Fund

Description

Kynexis announced the closing of a €40 million Series A extension, increasing total Series A financing to €97 million. The financing was led by Novartis Venture Fund, with participation from existing investors. It will support close-out activities for a Phase 2 study of KYN-5356 for cognitive impairment. The company is also preparing for registrational studies and aims to advance towards additional cognitive disorders.

Who to call at Kynexis, and when

A new round usually means Kynexis is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kynexis raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kynexis, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kynexis. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kynexis

Location

North Holland, Netherlands

About

Kynexis is a clinical-stage biotechnology company focused on improving cognition for people living with brain diseases. The company is advancing KYN-5356, a potential first-in-class investigational medicine aimed at treating cognitive impairment associated with schizophrenia. Kynexis aims to address cognitive dysfunction across multiple neurological and neurodegenerative disorders. The company is on track to report topline results from its Phase 2 study by the end of 2026.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kynexis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Kynexis's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Kynexis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.